SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 5.7% Passive Stake in Seres Therapeutics Inc.
Beneficial Ownership Report
FMR LLC and its Chairman and CEO, Abigail P. Johnson, have filed an amended Schedule 13G, reporting a 5.7% beneficial ownership stake in Seres Therapeutics Inc. as of May 30, 2025.
Summary
- FMR LLC and Abigail P. Johnson jointly reported beneficial ownership of 493,608 shares of Seres Therapeutics Inc. common stock.
- This ownership represents 5.7% of the total outstanding common stock of Seres Therapeutics Inc.
- FMR LLC holds sole voting power over 493,169 shares and sole dispositive power over 493,608 shares.
- Abigail P. Johnson, as a control person of FMR LLC, is deemed to beneficially own the same 493,608 shares with sole dispositive power.
- The filing is an Amendment No. 13 to a previous Schedule 13G, indicating an update to their reported ownership.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: Neutral. This is a factual, legally mandated disclosure of beneficial ownership, not a performance report or strategic announcement. It indicates a significant, passive institutional stake.
Positives
- Increased transparency regarding significant institutional ownership in Seres Therapeutics Inc.
- Indicates continued passive investment interest from a major financial institution (FMR LLC/Fidelity).
Future Outlook
NA
Management Comments
- "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
This filing is a routine disclosure of a significant passive ownership stake by a major institutional investor, FMR LLC (Fidelity), in a biotechnology company, Seres Therapeutics Inc. Such disclosures are common and reflect institutional portfolio management decisions rather than specific industry trends, though a significant stake can signal long-term interest in the sector or company.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially signaling confidence or stability from a major holder.
- Investment Professionals: Offers data for tracking institutional ownership and understanding the shareholder base of Seres Therapeutics Inc.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for Stephanie J. Brown on behalf of FMR LLC. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC where the Power of Attorney (accession number -23-000003) was incorporated by reference. |
| 2023-01-26 | Effective date of Power of Attorney for Stephanie J. Brown on behalf of Abigail P. Johnson. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC where the Power of Attorney (accession number -23-000038) was incorporated by reference. |
| 2025-05-30 | Date of event which requires the filing of this statement (beneficial ownership snapshot date). |
| 2025-06-05 | Date of signing and filing of this Schedule 13G Amendment No. 13. |
Keywords
SERES THERAPEUTICS INC, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.